AG
TVTX icon

Artal Group’s Travere Therapeutics TVTX Stock Holding History

Artal Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-511,784
Closed -$11.5M – 132
2023
Q1 		$11.5M Buy
511,784
+11,784
+2% +$250K 0.68% 36
2022
Q4 		$10.5M Buy
+500,000
New +$10.6M 0.59% 41

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Artal Group's TVTX Position: Q2 2023 in Review

Artal Group sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 511,784 shares — an estimated $11.5M sold.

Artal Group first reported a position in TVTX in Q4 2022 and held it in 2 quarters. The position peaked at $11.5M in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

  • Artal Group reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Artal Group sold 511,784 Travere Therapeutics shares in Q2 2023, an estimated $11.5M.
  • Artal Group first reported a position in Travere Therapeutics in Q4 2022 and held it in 2 quarters.
  • Artal Group's Travere Therapeutics position peaked at $11.5M in Q1 2023.
  • 169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.